Clinical trials: Coronavirus 2019
Coronavirus Infection
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.
- Trial name
- NCT04442230
- Testing
- NasoVAX
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Altimmune, Inc.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Infection of Upper Respiratory Tract Caused by 2019-nCoV
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
- Trial name
- NCT06042764
- Testing
- SA55 Injection
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Elderly People Institutionalized in Long-term Care Services
Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions
The main objective of this study is to describe the humoral and cellular response to BNT162b2 vaccination in people over age 75 institutionalized in the long-term care units of the Paris Public Hospitals (APHP)
- Trial name
- COGEVAX-BIO (NCT04961502)
- Testing
- Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gérond'if
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19, Coronavirus Disease 2019
Tele-Physiotherapy After COVID-19 Hospitalization
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), is a multisystem infectious disease which has led to a global pandemic.
- Trial name
- NCT04895371
- Testing
- Tele-physiotherapy group, Control group
- Where
- Iran
- Volunteers
- 72 people
- Sponsor
- Tehran University of Medical Sciences
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
- Conditions
- Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
- Trial name
- NCT03183570
- Testing
- [18F]FP-R01-MG-F2
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Stanford University
Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea.
- Trial name
- NCT07089680
- Testing
- Nirmatrelvir/Ritonavir
- Where
- 7 sites in South Korea
- Volunteers
- 937 people
- Sponsor
- Pfizer
COVID 19
Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients
More cases of COVID-19 pandemic are being reported daily around the world. It is highly infectious and, over 7 million people have been infected and more than 400,000 people have died globally till this date.
- Trial name
- HCQ-COVID19 (NCT04437693)
- Testing
- Hydroxychloroquine
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
COVID-19, Respiratory Failure
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial
Trial design: Prospective, multi-centre, randomised, pragmatic, double blind trial Methods: Participants: Adult (>18 years) within 24 hours of admission to intensive care unit with proven or suspected COVID-19 infection, whether…
- Trial name
- AZIQUINE-ICU (NCT04339816)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- Czechia
- Volunteers
- 3 people
- Sponsor
- Frantisek Duska, MD, PhD
Androgenetic Alopecia, Coronavirus Disease 2019
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia.
- Conditions
- Androgenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
- Trial name
- NCT04898166
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Syeda Mahanum Ali
COVID
Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study
France and especially the region "Grand Est" have been damaged by the COVID-19 pandemic. This pandemic resulted in a reorganization of the hospitalization sectors.
- Trial name
- COMETE-19 (NCT04430322)
- Where
- France
- Volunteers
- 1,045 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Covid-19, Hydrogen/Oxygen Mixed Gas
Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19)
This was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2-O2 (66% hydrogen; 33%…
- Conditions
- Covid-19, Hydrogen/Oxygen Mixed Gas, Dyspnea
- Trial name
- NCT04378712
- Testing
- Hydrogen Oxygen Generator with Nebulizer, Standard-of-care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
COVID-19 Vaccine Adverse Reaction, Lower Urinary Tract Symptoms
COVID-19 Vaccines and the Development of New LUTS
This study was conducted to check whether coronavirus disease 2019 (COVID) vaccines have a relationship with LUTS or not in a healthy and mostly medically free population.
- Trial name
- NCT05582525
- Where
- Jordan
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- The Hashemite University
Coronavirus Disease 2019
Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura
At the end of January 2020, the international community was informed of the presence of a new viral disease that started in Wuhan (China) and spread rapidly throughout the world.
- Trial name
- COVIXTREM (NCT04724850)
- Where
- Spain
- Volunteers
- 440 people
- Sponsor
- Juan Fernando Masa Jiménez
COVID, Severe Acute Respiratory Syndrome
Obesity and Mortality of Critically Ill Patients With COVID-19
Disproportionate impact of COVID-19 in patients with obesity is now well established. Obesity is associated with severe forms of COVID-19 and may be a risk factor of intensive care unit (ICU) admission.
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Obesity, Comorbidities and Coexisting Conditions
- Trial name
- COV-OB-ICU (NCT04425213)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know.
- Trial name
- NCT05815485
- Testing
- Azeliragon
- Where
- 3 sites in United States
- Volunteers
- 144 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Covid19, Distress, Emotional
The Practice of Providing Palliative Care in the Situation of the COVID-19 (Coronavirus Disease 2019) Pandemic in Czech Republic
Pandemic of coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2) causing the disease COVID-19 (Coronavirus Disease 2019) overwhelmed healthcare and brought new challenges and stressful situations.
- Trial name
- PEOpLe-C19 (NCT04910243)
- Testing
- Questionnaire Survey
- Where
- Czechia
- Volunteers
- 307 people
- Sponsor
- Brno University Hospital
Coronavirus Disease 2019 (COVID-19)
Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available.
- Trial name
- NCT04346368
- Testing
- BM-MSCs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
COVID-19
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in…
- Trial name
- NCT04542694
- Testing
- Favipiravir, Standard of care
- Where
- 5 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Promomed, LLC